Clinical Trial

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-08.
Trial Details
NCT Number NCT05994131
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Conditions NSCLC
Enrollment 110 participants
Start Date 2023-07-13
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-30